Hormone Test For Hot Flashes: Which Labs Matter Most

A hormone test for hot flashes isn't one assay. The right test depends on the person's age, sex, symptom pattern, and what their provider is trying to rule out. For women 45 and older with typical vasomotor symptoms, current guidelines from NICE and the International Menopause Society treat menopause as a clinical diagnosis. Routine FSH or estradiol testing isn't recommended in that group (NICE, 2024). For men, hot flashes point to severe testosterone deficiency or androgen-deprivation therapy, and the indicated test is repeated morning total testosterone, not a menopause panel (Bhasin et al., 2018). Knowing which markers apply to a specific situation may help clients and their providers focus testing on the clinical question at hand.

Marek Diagnostics offers direct-access lab testing that lets clients order the specific markers a provider recommends. Options range from single-marker tests like estradiol or FSH to full hormone lab panels that cover multiple markers in a single blood draw.

A hormone test for hot flashes is any blood test measuring the hormones tied to thermoregulation and reproductive function. The most commonly ordered markers are estradiol, FSH, total testosterone, free testosterone, TSH, and progesterone. Which ones belong in a given workup depends entirely on the clinical question being asked, and guidelines differ by age and sex.

Causes Of Hot Flashes Beyond Menopause

Hot flashes, or vasomotor symptoms, happen when the body's thermoregulatory center in the hypothalamus narrows the thermoneutral zone. That zone is the range of core temperatures the body tolerates before triggering a cooling response. Lower estrogen appears to narrow it. Even a small rise in core temperature can then trigger flushing, sweating, and rapid heart rate.

Menopause accounts for the majority of cases in women. Up to about 80% of women in the menopausal transition experience vasomotor symptoms (Menopause Society, 2022).

But hot flashes occur outside menopause for several reasons. In men, severe testosterone deficiency triggers vasomotor symptoms through the same estradiol pathway. About 70% of men on androgen-deprivation therapy for prostate cancer report hot flashes (Taylor et al., 2016). Taylor et al. found that estradiol deficiency, rather than testosterone loss alone, appeared to be a primary mediator. Hot flash frequency increased once estradiol dropped into the 5-9.9 pg/mL range compared with 10-14.9 pg/mL (38% vs. 16% of visits).

Other causes span both sexes: thyroid disease (particularly hyperthyroidism), certain medications (opioids, antidepressants, steroids, GnRH agonists), premature ovarian insufficiency in women under 40, cancer treatments, and rare neuroendocrine tumors. Each requires a different testing path.

Which Hormone Tests Are Ordered For Hot Flashes?

No single "hot flash panel" exists in clinical guidelines. The test or tests a provider selects depend on whether the goal is to confirm a hormonal cause, rule one out, or narrow the differential. The table below shows which tests guidelines support for common clinical scenarios.

Marek Diagnostics carries each of these as an individual biomarker test or as part of a bundled panel. Clients who want a single marker can order a sensitive estradiol test without purchasing a full panel.

Do Women Over 45 Need A Hormone Blood Test?

For most women 45 and older with typical hot flashes and amenorrhea lasting 12 months, the answer from clinical guidelines is no. NICE states that age over 45, typical symptoms, and cycle cessation are sufficient to confirm the menopause transition without biochemical testing (NICE, 2024). The International Menopause Society's 2025 position agrees. Diagnosis is clinical, and STRAW+10 staging uses cycle pattern rather than blood work.

FSH can swing substantially during perimenopause. A normal FSH result doesn't exclude the transition, and a high FSH doesn't reliably time treatment. That is the core reason guidelines discourage routine measurement in the over-45 group.

Testing does have a role in specific situations. Providers may consider FSH for women aged 40-45 with symptoms and irregular cycles, for women under 40 when premature ovarian insufficiency is suspected (two FSH samples drawn 4-6 weeks apart), and in selected cases involving progestogen-only contraception after age 50. Estradiol testing may be warranted when relief from prescribed therapy is inadequate, adverse effects persist, or the client has premature ovarian insufficiency. Marek Diagnostics offers menopause testing panels that cover FSH, estradiol, progesterone, and supporting markers in a single draw for these situations.

How Are Hot Flashes Tested In Men?

Hot flashes in men may indicate significant androgen deficiency rather than typical age-related change.

The diagnostic protocol calls for two early-morning total testosterone measurements drawn on separate days, fasting, before 10 a.m., on the same lab and assay method. The AUA rates the two-draw protocol as a strong recommendation (Grade A) and considers total testosterone consistently below 300 ng/dL a reasonable cut-off to support the diagnosis (moderate recommendation, Grade B) (Mulhall et al., 2018). The Endocrine Society uses the lower limit of a reliable assay rather than a single universal number and requires symptoms alongside the lab finding (Bhasin et al., 2018).

Free testosterone by equilibrium dialysis or a validated calculation may be added when total testosterone is borderline or SHBG is likely altered. Obesity, opioid use, thyroid disease, and liver disease all shift SHBG. An SHBG blood test can clarify whether binding-protein levels are skewing the total number.

Taylor et al. (2016) analyzed vasomotor symptoms in hypogonadal men who were not on androgen-deprivation therapy and found estradiol deficiency appeared to be a primary mediator. Hot flash frequency increased from 16% of visits when estradiol was in the 10-14.9 pg/mL range to 38% of visits in the 5-9.9 pg/mL range (Taylor et al., 2016). That data supports a structured approach to the androgen axis (paired morning testosterone, then estradiol if indicated) rather than ordering a single random estradiol draw.

One caution: men on androgen-deprivation therapy for prostate cancer commonly develop hot flashes, with about 70% affected. But the Endocrine Society recommends against testosterone therapy in men with known prostate cancer (Bhasin et al., 2018). A total testosterone test can document the expected low level, but treatment decisions depend on the underlying condition and oncology input.

Thyroid, Medications, And Other Causes Of Flushing

Not every hot flash has a reproductive-hormone origin.

A thyroid panel starting with a TSH test can identify hyperthyroidism, which speeds metabolism and produces flushing, sweating, and rapid heart rate that mimic vasomotor symptoms. If TSH is suppressed, free T4 and free T3 follow.

Medications are another common trigger. Opioids, some antidepressants, steroids, and GnRH agonists can all produce hot flashes through different mechanisms. The Endocrine Society lists opioids and glucocorticoids as causes of secondary hypogonadism in men (Bhasin et al., 2018). Stopping or adjusting the medication may help resolve symptoms in some cases, though a provider needs to weigh the risks of the underlying condition being treated.

Less common causes worth ruling out include carcinoid syndrome (flushing with diarrhea, typically confirmed via 5-HIAA or chromogranin A), pheochromocytoma (episodic flushing with hypertension), and medullary thyroid carcinoma. These sit outside the sex-steroid assays and require different testing pathways entirely.

New nonhormonal medications for menopausal hot flashes, fezolinetant (approved 2023) and elinzanetant (approved October 2025), carry their own lab requirements. The FDA added a boxed warning for fezolinetant in December 2024 after a postmarketing report of serious liver injury. The required monitoring is a liver panel (ALT, AST, alkaline phosphatase, bilirubin) before treatment, monthly for 3 months, then at months 6 and 9 (FDA, 2024). That is liver monitoring, not a sex-hormone panel.

What Hormone Test Results Can Show

Hormone test results don't diagnose menopause or hypogonadism on their own. They provide data that a provider interprets alongside symptoms, medical history, and physical findings.

For women: an elevated FSH (above 30 IU/L, the threshold British Menopause Society practice standards cite as suggesting ovarian insufficiency) supports the clinical picture when testing is indicated (NICE, 2024). A low estradiol adds to that picture, but a normal estradiol during perimenopause doesn't rule it out since levels swing from cycle to cycle.

For men: two morning total testosterone results consistently below the assay's lower limit, paired with symptoms like reduced libido, fatigue, or hot flashes, support a hypogonadism evaluation. LH and FSH help distinguish primary from secondary causes. Elevated LH points toward a testicular origin; low or normal LH with low testosterone suggests a pituitary or hypothalamic problem. Prolactin and iron studies may follow.

A single afternoon blood draw, a random estradiol without paired testosterone in a man, or a self-ordered panel interpreted without clinical context all carry a risk of misclassification. The International Menopause Society's 2025 statement notes that routine estradiol to set menopausal hormone therapy dose is generally not recommended, with exceptions for poor relief, persistent adverse effects, and premature ovarian insufficiency. Testing decisions and next steps work best as a shared conversation between the client and a provider who can weigh the full clinical picture.

Preparing For A Hormone Blood Draw

Timing and preparation affect hormone test accuracy. Testosterone follows a circadian rhythm, peaking between about 7 and 10 a.m. and falling through the afternoon. Both the AUA and the Endocrine Society specify early-morning fasting draws for diagnostic testosterone measurements.

FSH and estradiol don't follow the same daily cycle, but menstrual cycle timing matters in premenopausal women. FSH drawn during the early follicular phase (days 2-5 of the cycle) provides the most interpretable baseline. For women in perimenopause with irregular cycles, the provider may simply note the date relative to the last period.

General preparation: fast for at least 8 hours before the draw, stay hydrated with water, avoid intense exercise the evening before, and report current medications. Biotin supplements, hormonal contraception, and opioids can each affect specific assay results. Reporting them lets the lab and provider account for interference.

Marek Diagnostics coordinates blood draws at labs across more than 2,000 U.S. locations. Clients can order from individual biomarkers or select a women's health panel that bundles the relevant markers for a hormone test for hot flashes evaluation.

The FDA updated testosterone product labeling in February 2025 to add a blood-pressure warning and remove the previous cardiovascular boxed warning after the TRAVERSE trial data, while keeping the Limitation of Use for age-related hypogonadism (FDA, 2025; Lincoff et al., 2023). Testosterone products remain approved only for men with deficiency tied to a medical condition, and the TRAVERSE trial's secondary signals (higher atrial fibrillation and pulmonary embolism in the testosterone group) travel with that context. A hormone test for hot flashes may be part of the diagnostic workup when testing is indicated, but any treatment that follows requires confirmed deficiency, clinical evaluation, and ongoing monitoring by a licensed provider.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Do women over 45 need a blood test to confirm menopause?

In most cases, no. NICE and the International Menopause Society state that age over 45, typical vasomotor symptoms, and 12 months of amenorrhea are sufficient for a clinical menopause diagnosis. FSH is not recommended as a routine confirmation test in that group because it fluctuates during perimenopause and a single value doesn't reliably time the transition.

Can FSH be normal and someone still be in perimenopause?

Yes. FSH swings from week to week during perimenopause, so a normal result doesn't exclude the transition. The Menopause Society and NICE use cycle pattern and symptoms as the primary staging method rather than a single blood value.

Can men get hot flashes from low testosterone?

Yes, when deficiency is severe. About 70% of men on androgen-deprivation therapy experience hot flashes. Taylor et al. (2016) found that estradiol deficiency, driven by low testosterone, appeared to be a primary mediator of vasomotor symptoms in hypogonadal men. Guidelines call for two fasting, early-morning total testosterone draws on separate days.

Should estradiol be checked to set a hormone therapy dose?

The International Menopause Society's 2025 position states that routine estradiol measurement to set menopausal hormone therapy dose is generally not recommended. Exceptions include inadequate symptom relief, persistent adverse effects, and premature ovarian insufficiency or early menopause. Providers adjust based on clinical response in most cases.

What lab work is required before fezolinetant for hot flashes?

A liver panel, not a sex-hormone panel. The FDA added a boxed warning for fezolinetant in December 2024 after a postmarketing report of serious liver injury. The required schedule includes ALT, AST, alkaline phosphatase, and bilirubin before the first dose, monthly for 3 months, then at months 6 and 9.

Does a normal testosterone result rule out a hormonal cause of hot flashes?

Not on its own. A single afternoon testosterone draw can miss the morning peak and produce a falsely normal result. The AUA requires two morning values. Thyroid disease, medications, and rare conditions like carcinoid syndrome can also cause flushing and sit outside the sex-steroid assays.

Can someone order a hormone test for hot flashes without a referral?

Marek Diagnostics offers direct-access lab testing across more than 2,000 U.S. locations. Clients can select individual markers or bundled panels and have results reviewed by a provider. If testosterone therapy is considered after results come back, a confirmed diagnosis and clinical evaluation are required before any prescription, as testosterone is a Schedule III controlled substance.

References

• Cureus. 2024;16(3):e55729.

• FDA Drug Safety Communication, December 2024.

• FDA Testosterone Labeling Changes, February 2025.

• J Clin Endocrinol Metab. 2016;101(9):3479-3486.

• J Clin Endocrinol Metab. 2018;103(5):1715-1744.

• J Urol. 2018;200(2):423-432.

• Menopause. 2022;29(7):767-794.

• N Engl J Med. 2023;389:107-117.

• NICE CKS: Menopause Diagnosis.